Recent News

The FDA Releases Safer Alternatives to Zantac As Investigation Into Contaminated Ranitidine-Based Medication Continues

As the FDA continues its investigation into the carcinogenic contamination of Zantac and other ranitidine-based drugs, the agency also released an extensive list of alternative medications that are deemed safe from toxic contaminants. Here, the Baltimore pharmaceutical liability attorneys at Peter Angelos, P.C. discuss updates to the Zantac contamination investigation as well as provide an…

Read More...

An Overview of the FDA Death Database Malfunction

Researchers have reported that the miscategorization of a slew of patient deaths by the FDA points to the potential unreliability of their adverse events database. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss how current protocols for reporting patient death through the FDA’s Manufacturer and User Facility Device Experience (MAUDE)…

Read More...

Zantac Manufacturer Recalls Medication Due to Confirmed Contamination

Sandoz Inc. has voluntarily recalled the generic version of common medication Zantac after the medication was confirmed to be contaminated with a human carcinogen. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the updates to the ongoing Zantac claims.  Global health regulators recently raised concerns about the possibility that the…

Read More...

The FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants

In response to the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) linked to Allergan BIOCELL textured breast implants, the Food and Drug Administration (FDA) has requested that Allergan voluntarily recall select breast implants and tissue expanders. As a result of the request for recall, Allergan has agreed to take its products associated with…

Read More...

FDA Issues Black Box Warning for Xeljanz and Xeljanz XR

In July 2019, the Food and Drug Administration (FDA) placed a Black Box Warning, the highest possible warning the FDA can mandate, on Pfizer’s blockbuster immunology drugs Xeljanz and Xeljanz XR. These new warnings will alert patients of risks including an increased risk of blood clots—and potentially, death. Here, the Baltimore pharmaceutical liability attorneys at…

Read More...

FDA Releases Millions of Records of Incidents Involving Medical Devices

On Friday, June 21st, the Food and Drug Administration (FDA) published previously undisclosed reports of incidents and post-surgical complications involving medical devices, including reports on implantable cardiac defibrillators, pacemaker electrodes and dental implants. Here, the product liability attorneys at The Law Offices of Peter Angelos outline the details of these incidents. Advocates for public transparency…

Read More...

FDA Includes Black Box Warning on Gout Medicine Uloric

As of February 2019, the U.S. Food and Drug Administration has stated that there is a higher risk of death associated with gout medicine Uloric (febuxostat) compared to other gout medicines. The FDA has now included a Black Box Warning for Uloric as a result of the recent findings. Here, the pharmaceutical liability attorneys at…

Read More...

FDA: Clinical Trials Show Increased Risk of Amputation with Invokana

Recent safety communications published by the US Food and Drug Administration indicate that type 2 diabetes drug, Invokana (canagliflozin), can cause increased risk for foot and leg amputations. This announcement was made after data from two clinical studies showed that such amputations were necessary in nearly twice as many patients taking Invokana as compared to…

Read More...

FDA Confirms Link Between Breast Implants and Cancer

The Food and Drug Administration has announced that those who undergo breast augmentation using breast implants have an increased risk for developing anaplastic large cell lymphoma—a rare form of non-Hodgkins lymphoma. According to safety communications, the FDA identified a possible link between the implants and anaplastic large cell lymphoma (ALCL) in 2011. At the time…

Read More...

Class I Recall: Zimmer Biomet Comprehensive Reverse Shoulder

Zimmer Biomet has issued a Class I recall for its Comprehensive Reverse Shoulder as the devices have exhibited higher rates of fracturing than previously stated. In December 2016, Zimmer Biomet issued an Urgent Medical Device Recall Notice to customers who may have undergone surgery in which a Comprehensive Reverse Shoulder was implanted.  This recall has…

Read More...